Dataset Information

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine^® in Subjects with Eyelid Eczema.

ABSTRACT:

Background

Eyelid eczema (EE) is frequently observed in patients with an allergic or atopic diathesis. As for atopic eczema, restoring the skin barrier of the periocular region together with relieving clinical signs and symptoms is important in the management of EE. This study assessed the benefit and tolerance of a dedicated dermocosmetic (DC) in subjects with EE.

Materials and methods

Open-label study in adults with EE and sensitive skin. The DC was applied twice daily for 28 days. Dermatological signs (eczema, desquamation/dryness, erythema, swelling, roughness) and symptoms (itching, prickling, heat/burning sensation, tightness) on the periorbital region, as well as ophthalmological evaluation were assessed at Day 0, 14 and 28. Subjects assessed quality of life (QOL) using DLQI, the perceived benefit and cosmetic acceptability of the DC.

Results

Overall, 41 subjects were included; 59% were women. The mean age was 52.4±15.8 years; all subjects had periorbital sensitive skin. The DC immediately reduced the intensity of itching, prickling, heat/burning sensation and tightness. Clinical signs and symptoms had all significantly (p<0.001) improved by Day 14 and were sustained to Day 28. The DC significantly (p<0.001) improved the perception of irritation (73%) and swelling (66%) while soothing (59%) the periorbital skin regions at Day 28. QOL had improved at Day 28 (0.82±1.0) compared to Day 0 (4.17±2.23). No local adverse reactions were reported. Ophthalmological examinations paralleled the excellent dermatological tolerance of DC.

Discussion

The tested DC is highly efficacious in reducing clinical signs and symptoms of eyelid eczema and was well tolerated.

Clinicaltrialsgov identifier

NCT05540496.

SUBMITTER: Tan J

PROVIDER: S-EPMC9880017 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine<sup>®</sup> in Subjects with Eyelid Eczema.

Tan Jerry J Demessant Ann'Laure A Le Dantec Guénaelle G Le Floc'h Caroline C Kerob Delphine D

Clinical, cosmetic and investigational dermatology 20230120

<h4>Background</h4>Eyelid eczema (EE) is frequently observed in patients with an allergic or atopic diathesis. As for atopic eczema, restoring the skin barrier of the periocular region together with relieving clinical signs and symptoms is important in the management of EE. This study assessed the benefit and tolerance of a dedicated dermocosmetic (DC) in subjects with EE.<h4>Materials and methods</h4>Open-label study in adults with EE and sensitive skin. The DC was applied twice daily for 28 da ...[more]

PMID: 36711070

Similar Datasets

Project description:BackgroundRehabilitation robotics is a field of study which aims to understand and augment rehabilitation through the use of robotics devices.ObjectiveThis proof of concept study aimed to test the safety (no. adverse events, incidence of infection), feasibility (program demand, adherence, participant satisfaction) and efficacy (Peak Oxygen uptake (VO2peak), 6-min walk test, gait speeds, Canadian Occupational Performance Measure, quality of life) of Lokomat® and Armeo®Spring training in children and adolescents and young adults (AYAs) during or soon after cancer treatment.MethodThis was a 6-week single arm pre-post study. Cancer patients with significant musculoskeletal, neurological, gait and/or upper limb deficiency aged 5 to 25 years were recruited. The rehabilitation program included access to two robotic orthoses: the Lokomat® and/or Armeo®Spring. Robotic devices utilised real-time biofeedback and computer games to engage and guide participants through a repetitive functional range of movement aimed at improving functional deficiencies. Progressive increases in exercise intensity and duration were encouraged.ResultsTwentey-eight participants were approached for study; twenty-one consented. Seventy-six percent completed the six-week intervention with an overall adherence of 83%. The mean participant satisfaction score was 8.8/10. Forty-nine adverse events were recorded throughout the course of the study, forty-five grade 1, three grade 2 and one grade 3. No adverse events led to withdrawal from the study. Preliminary efficacy results indicate large beneficial effects on VO2peak (r = 0.63), 10 m comfortable pace walk (r = 0.51) and maximal pace walk (r = 0.60), 6-min walk test (r = 0.60), maximal back and leg strength (r = 0.71), trunk flexibility (r = 0.60), The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30) (r = 0.61), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT F) r = 0.53 and the Canadian Occupational Performance Measure, satisfaction (r = 0.88) and performance scores (r = 0.83), and moderate beneficial effects on Leisure Score Index (LSI) (r = 0.30).ConclusionOur results suggest that Lokomat® and Armeo®Spring training is safe and feasible for use in children and AYAs who are currently undergoing or have recently completed cancer therapy. A larger controlled trial investigating the efficacy of robotics rehabilitation in this cohort is warranted.

Dataset Information

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine^® in Subjects with Eyelid Eczema.

Background

Materials and methods

Results

Discussion

Clinicaltrialsgov identifier

Publications

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine<sup>®</sup> in Subjects with Eyelid Eczema.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine® in Subjects with Eyelid Eczema.

Background

Materials and methods

Results

Discussion

Clinicaltrialsgov identifier

Publications

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine<sup>®</sup> in Subjects with Eyelid Eczema.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Tolerance and Efficacy of a Dermocosmetic Containing Neurosensine^® in Subjects with Eyelid Eczema.